BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 11156402)

  • 21. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells.
    Wang RF; Wang HY
    Nat Biotechnol; 2002 Feb; 20(2):149-54. PubMed ID: 11821860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
    Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
    Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
    Zeh HJ; Perry-Lalley D; Dudley ME; Rosenberg SA; Yang JC
    J Immunol; 1999 Jan; 162(2):989-94. PubMed ID: 9916724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
    Tüting T; DeLeo AB; Lotze MT; Storkus WJ
    Eur J Immunol; 1997 Oct; 27(10):2702-7. PubMed ID: 9368629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
    Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
    Tan XH; Wan YH
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
    Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
    Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo.
    Tang XD; Wan Y; Chen L; Chen T; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
    Cancer Res; 2008 Mar; 68(5):1529-37. PubMed ID: 18316618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.
    Ribas A; Butterfield LH; Hu B; Dissette VB; Meng WS; Koh A; Andrews KJ; Lee M; Amar SN; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Apr; 60(8):2218-24. PubMed ID: 10786687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.
    Melcher A; Todryk S; Bateman A; Chong H; Lemoine NR; Vile RG
    Cancer Res; 1999 Jun; 59(12):2802-5. PubMed ID: 10383135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
    Griffiths E; Ong H; Soloski MJ; Bachmann MF; Ohashi PS; Speiser DE
    Cancer Res; 1998 Oct; 58(20):4682-7. PubMed ID: 9788622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity.
    Steitz J; Brück J; Gambotto A; Knop J; Tüting T
    Gene Ther; 2002 Feb; 9(3):208-13. PubMed ID: 11859424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
    van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
    Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
    Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
    Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
    Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S; Wang F; He X; He Y; Li D; Sun S
    Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.